Drugs / LY3875383
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05609825 | Nov 2022 → Jan 2024 | hypertriglyceridemia | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3875383 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05609825 ↗ |
| Route | Subcutaneous | “Single-ascending doses of LY3875383 administered subcutaneously (SC).” NCT05609825 ↗ |